AUPH (STOCKS)
Aurinia Pharmaceuticals Inc
$15.180000
-0.270000 (-1.75%)
Prev close: $15.450000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Kevin C. Tang
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,143.11M
- Employees
- 300
- P/E (TTM)
- 6.75
- P/B (TTM)
- 3.34
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $311.51M |
| Benefits Costs and Expenses | $68.21M |
| Cost Of Revenue | $30.04M |
| Costs And Expenses | $160.76M |
| Gross Profit | $281.47M |
| Operating Expenses | $147.70M |
| Research and Development | $39.85M |
| Other Operating Expenses | $123.54M |
| Operating Income/Loss | $150.75M |
| Income/Loss From Continuing Operations After Tax | $314.11M |
| Income/Loss From Continuing Operations Before Tax | $201.79M |
| Income Tax Expense/Benefit | -$153.75M |
| Income Tax Expense/Benefit, Deferred | -$155.81M |
| Net Income/Loss | $314.11M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $314.11M |
| Net Income/Loss Available To Common Stockholders, Basic | $314.11M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.39 |
| Diluted Earnings Per Share | $2.29 |
| Basic Average Shares | 393,468,000 |
| Diluted Average Shares | 406,918,000 |
| Assets | $792.26M |
| Current Assets | $541.32M |
| Inventory | $45.15M |
| Other Current Assets | $496.17M |
| Noncurrent Assets | $250.94M |
| Fixed Assets | $1.86M |
| Other Non-current Assets | $249.08M |
| Liabilities | $177.40M |
| Current Liabilities | $99.89M |
| Accounts Payable | $1.74M |
| Wages | $11.84M |
| Other Current Liabilities | $86.32M |
| Noncurrent Liabilities | $77.51M |
| Equity | $614.86M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $614.86M |
| Liabilities And Equity | $792.26M |
| Net Cash Flow From Operating Activities | $175.24M |
| Net Cash Flow From Operating Activities, Continuing | $175.24M |
| Net Cash Flow From Investing Activities | $12.84M |
| Net Cash Flow From Investing Activities, Continuing | $12.84M |
| Net Cash Flow From Financing Activities | -$61.25M |
| Net Cash Flow From Financing Activities, Continuing | -$61.25M |
| Net Cash Flow | $126.83M |
| Net Cash Flow, Continuing | $126.83M |
| Comprehensive Income/Loss | $313.74M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $313.89M |
| Other Comprehensive Income/Loss | $71.39M |